Encompass Health CEO granted over 113K shares

Encompass Health Corp reported that President and CEO Mark J. Tarr acquired company stock through equity awards, rather than open-market purchases.

Accepted by SEC EDGAR 02/20/2026 - 03:41 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Encompass Health Corp reported that President and CEO Mark J. Tarr acquired company stock through equity awards, rather than open-market purchases. On February 19, 2026, he received 12,796 shares of Encompass Health common stock at $0.00 per share, increasing his direct holdings to 490,812 shares. This issuance of restricted stock resulted from meeting performance criteria under a performance share unit award granted on February 23, 2023.

On February 18, 2026, Tarr was also granted 100,946 shares of restricted stock at $0.00 per share, bringing his direct ownership to 478,016 shares immediately after that grant. This award was an annual restricted stock grant made under the corporation's 2025 Omnibus Performance Incentive Plan.

Insider Trade Summary

Grant/Award: 113,742 shares

Grant/Award 2 txns

Insider Tarr Mark J

Role President & CEO

Type	Security	Shares	Price	Value
Grant/Award	Encompass Health Common Stock	12,796	$0.00	$0.00
Grant/Award	Encompass Health Common Stock	100,946	$0.00	$0.00

Holdings After Transaction: Encompass Health Common Stock — 490,812 shares (Direct)

Holdings Before and After: Encompass Health Common Stock, 377,070 to 490,812 shares (Direct)

Footnotes (2)

1. F1. This issuance of restricted stock is the result of the satisfaction of performance criteria set out in the terms of a performance share unit award made on February 23, 2023.
2. F2. Annual award of restricted stock pursuant to the Corporation's 2025 Omnibus Performance Incentive Plan.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Encompass Health (EHC) disclose in this Form 4 for Mark J. Tarr?

Encompass Health disclosed that President and CEO Mark J. Tarr acquired company shares through equity awards, not market purchases. He received restricted stock tied to performance criteria and an annual award under the 2025 Omnibus Performance Incentive Plan.

How many Encompass Health shares did CEO Mark J. Tarr receive in these awards?

Mark J. Tarr received 12,796 restricted shares on February 19, 2026 and 100,946 restricted shares on February 18, 2026. Both issuances were at $0.00 per share as compensation-related stock awards, rather than cash purchases in the open market.

What is the nature of the 12,796-share Encompass Health stock issuance to Mark J. Tarr?

The 12,796-share issuance is restricted stock resulting from satisfying performance criteria in a performance share unit award granted on February 23, 2023. It represents stock delivered after meeting pre-set goals, rather than a discretionary stock market transaction.

What plan governs the 100,946-share award to Encompass Health CEO Mark J. Tarr?

The 100,946-share grant is an annual restricted stock award made under Encompass Health’s 2025 Omnibus Performance Incentive Plan. This plan provides equity-based compensation, and the shares were issued at $0.00 per share as part of Tarr’s executive compensation.

How many Encompass Health shares does Mark J. Tarr own directly after these transactions?

After the February 19, 2026 restricted stock issuance, Mark J. Tarr directly owns 490,812 shares of Encompass Health common stock. The Form 4 shows this as his total direct holdings following the performance-based restricted stock award transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tarr Mark J

(Last) (First) (Middle)

9001 LIBERTY PARKWAY

(Street)

BIRMINGHAM AL 35242

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Encompass Health Corp [ EHC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Encompass Health Common Stock	02/18/2026		A		100,946(1)	A	$0	478,016	D
Encompass Health Common Stock	02/19/2026		A		12,796(2)	A	$0	490,812	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This issuance of restricted stock is the result of the satisfaction of performance criteria set out in the terms of a performance share unit award made on February 23, 2023.

2. Annual award of restricted stock pursuant to the Corporation's 2025 Omnibus Performance Incentive Plan.

	/s/ Patrick Darby, attorney-in-fact for Mark J. Tarr	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.